Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders
Takeda announced to have entered into a strategic partnership with Enzyre BV, a Radboudumc spin-off company. The partnership aims to accelerate the development of a diagnostic technology platform that improves the standard of care for patients with bleeding disorders.
Enzyre was founded in 2016 with the mission to save patients from bleeding to death with their Enzypad technology. Their vision is to create a point of care diagnostic platform that will measure a multitude of enzymatic reactions based on chemiluminescence.
Read the Takeda announcement here: https://lnkd.in/dJSqpRk
Related news items
Enzyre works towards cheaper care with integrated photonics9 June 2022
Integrated photonics is a technology that will be decisive in the coming years in terms of innovative solutions in healthcare.read more
Radboudumc and Terumo Europe N.V. sign collaboration agreement3 June 2022
Together, the two partners will improve existing treatments for cancer patients and develop new, personalized therapies. Focus will be on the clinical use of holmium-166 microspheres, small radioactive beads.read more
Investment in ARNE helps neonatologists make better decisions when treating newborn babies28 April 2022
ARNE B.V. has raised financing from Oost NL and venture builder NLC. ARNE supplies smart software with which neonatologists can make decisions based on data after the birth of a child.read more
Cell4Pharma enters into distribution agreement and strategic partnership with MatTek25 March 2022
MatTek Life Sciences will distribute Cell4Pharma’s ciPTEC renal cells and utilize the technology in the development of a new in vitro kidney model.read more